Ovarian Cancer | Specialty

The ovarian cancer condition center is a comprehensive resource for clinical news and expert insights on ovarian cancer. Read more at OncLive.

Relacorilant Combo Improves PFS, Trends Toward Superior OS in Platinum-Resistant Ovarian Cancer

June 2nd 2025

Relacorilant plus nab-paclitaxel showed meaningful PFS and OS gains, offering a potential new option for patients with platinum-resistant ovarian cancer.

Dostarlimab Plus Chemo With Maintenance Niraparib Generates Modest PFS Boost in Advanced Ovarian Cancer

June 2nd 2025

Dostarlimab/chemotherapy plus maintenance niraparib showed clinically modest PFS improvements vs niraparib alone in newly diagnosed advanced ovarian cancer.

OncLive’s FDA Approval Report: The Regulatory Rundown for May 2025

May 30th 2025

Here is your snapshot of all therapeutic options that were approved by the FDA in May 2025 spanning tumor types.

OncLive Polls Show Top Votes for Anticipated Gynecologic Cancer Abstracts at ASCO 2025

May 30th 2025

Experts from the gynecologic oncology space vote on their most anticipated abstracts on OncLive’s social media.

Experts Preview Key Presentations to Watch in Gynecologic Oncology at ASCO 2025

May 20th 2025

Experts highlight key abstracts and presentations to keep an eye on in gynecologic oncology at the 2025 ASCO Annual Meeting.

Five Under 5: Top Oncology Videos for the Week of 5/11

May 18th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, prostate cancer, chronic lymphocytic leukemia, and breast cancer.

Pembrolizumab-Based Regimen Yields PFS Benefit in Platinum-Resistant Ovarian Cancer

May 15th 2025

Pembrolizumab/paclitaxel with or without bevacizumab improved PFS vs placebo/chemotherapy with or without bevacizumab in platinum-resistant ovarian cancer.

Dr Grisham on the FDA Approval of Avutometinib/Defactinib for KRAS+ Recurrent Low-Grade Serous Ovarian Cancer

May 14th 2025

Rachel Grisham, MD, discusses the FDA approval of avutometinib plus defactinib for KRAS-mutated, recurrent low-grade serous ovarian cancer.

OVATION-3 Trial of IMNN-001 Seeks to Confirm Feasibility of Targeting IL-12 to Boost Immune Responses in Ovarian Cancer

May 13th 2025

Premal Thaker, MD, MS, discusses prior data supporting the ongoing investigation of IMNN-001 plus perioperative chemotherapy in ovarian cancer.

Dr Graham on the Significance of the FDA Approval of Mirvetuximab Soravtansine in Ovarian Cancer

May 12th 2025

Deena M. Atieh Graham, MD, discusses the FDA approval of mirvetuximab soravtansine.

Avutometinib/Defactinib Expands Treatment Options for KRAS-Mutant Low-Grade Serous Ovarian Cancer

May 12th 2025

Bradley Monk, MD, FACOG, FACS, discusses the FDA approval of avutometinib plus defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.

Five Under 5: Top Oncology Videos for the Week of 5/4

May 11th 2025

The top 5 OncLive videos of the week cover insights in myelodysplastic syndrome, lung cancer, hepatocellular carcinoma, colorectal cancer, and ovarian cancer.

The OncFive: Top Oncology Articles for the Week of 5/4

May 10th 2025

A doublet is approved for KRAS-mutated ovarian cancer, T-DXd followed by THP improves pCR rates in HER2+ breast cancer, and more from OncLive.

Dr Graham on Notable Ongoing Studies in Ovarian Cancer

May 9th 2025

Deena M. Atieh Graham, MD, discusses ongoing studies of note in patients with ovarian cancer following World Ovarian Cancer Day.

Dr Monk on the FDA Approval of Avutometinib and Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8th 2025

Bradley Monk, MD, FACOG, FACS, discusses the FDA’s accelerated approval of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.

FDA Approves Avutometinib Plus Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8th 2025

The FDA has granted accelerated approval to avutometinib plus defactinib (Avmapki Fakzynja) for select KRAS-mutated recurrent low-grade serous ovarian cancer.

ADCs and PARP Inhibitors Are Among 2025’s Practice-Changing Agents in Ovarian Cancer

May 8th 2025

Deena M. Atieh Graham, MD, highlights the current treatment paradigm in ovarian cancer, particularly PARP inhibitors and new ADCs in the space.

Dr Lee on the Mechanism of Action of Rina-S in FRα+ Platinum-Resistant Ovarian Cancer

May 1st 2025

Elizabeth Lee, MD, discusses the need for FRα-targeted therapies with differing payloads for patients with platinum-resistant ovarian cancer.

OncLive’s FDA Approval Report: The Regulatory Rundown for April 2025

May 1st 2025

Here is your snapshot for all therapeutic options that were cleared by the FDA in April 2025 spanning tumor types.

Dr Simpkins on the Predictive Utility of Cyclin E1 for Azenosertib Response in Ovarian Cancer

April 30th 2025

Fiona Simpkins, MD, discusses key findings from the phase 2 DENALI trial evaluating azenosertib in patients with platinum-resistant ovarian cancer.

x